Going further in the knowledge of Yondelis®; what's new in clinical trials? - Wikidata - wikimedia - TriplyDB

Going further in the knowledge of Yondelis®; what's new in clinical trials?

Going further in the knowledge of Yondelis®; what's new in clinical trials?

http://www.wikidata.org/entity/Q38232374

about

Trabectedin clinical cases: use according to indication in diverse clinical scenarios.

P2860

Q38515915-26899CF8-39B2-4E19-88B3-1EBD3F7D6881

P2860

Going further in the knowledge of Yondelis®; what's new in clinical trials?

http://www.wikidata.org/entity/Q38232374

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Going further in the knowledge of Yondelis®; what's new in clinical trials?

@en

type

label

Going further in the knowledge of Yondelis®; what's new in clinical trials?

@en

prefLabel

Going further in the knowledge of Yondelis®; what's new in clinical trials?

@en

P1433

Q38232374-F66FCF4E-B576-4D2D-B18A-EFA0B92316A4

P1476

Q38232374-7335DAC5-6F29-41A7-ACB2-99E52F167B67

P2860

Q38232374-01844EF4-7F76-4069-9297-F6C92D338E52

Q38232374-3FCDD59D-CB88-4278-981F-29B0DA1EB83B

Q38232374-414855EF-20E2-47AB-84D3-D22049EB39FA

Q38232374-4DFE708D-7885-46E2-8449-866FC13F0541

Q38232374-7462EE11-CB58-4845-98C1-EDFA1E3F6DE3

Q38232374-7B5A620C-4F63-4356-9D83-4FF23D32891D

Q38232374-C04F28BF-6F2A-4D4D-9377-1ADA1977A608

Q38232374-C9403288-2414-4507-A4A4-B5983BC34BFF

P304

Q38232374-243C3135-F875-4EB4-AEF9-8483E7BD582A

P31

Q38232374-161B9233-428B-46B1-B7CE-403F04F5E37D

P356

Q38232374-713A8D9D-23D8-464B-BBC9-170A125BEC0A

P407

Q38232374-09AEC406-AD1A-4A48-AE34-D9B1BF4CBCD2

P433

Q38232374-929A22FF-3DCD-42A2-86C2-9B5CADD8BCC2

P478

Q38232374-A09FCE50-6082-4BBB-ADBD-711A01F9E80E

P50

Q38232374-460ABC55-25E2-4DB6-967E-F8E433CF457E

P577

Q38232374-A02598C8-0479-4DC5-B39B-3C19597D78A5

P698

Q38232374-95F1D8D1-41C1-4581-AFE4-9CFDF55C2BEF

P356

P1433

Future Oncology

P1476

Going further in the knowledge of Yondelis®; what's new in clinical trials?

@en

P2860

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.

P304

s7-s12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.114

http://www.w3.org/2001/XMLSchema#string

P407

P433

8 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25048046

http://www.w3.org/2001/XMLSchema#string